Solving Today's Complex Pharma Manufacturing Challenges with Digital
Pharma Tech Outlook
Home » News

Solving Today's Complex Pharma Manufacturing Challenges with Digital

Pharma Tech Outlook | Friday, February 28, 2025

The pharma industry is unique in that it is a conservative and highly regulated industry with famously long product development cycles. Pharmaceutical companies are facing more pressure than ever as extended value chains and networks become more global and intricate in nature. Manufacturing process complexity is growing rapidly as therapies evolve from small to large molecules to cell and gene therapy and connected drug delivery devices. This has required the pharma industry to have new levels of analytical capability to solve their manufacturing challenges.

Some of the biggest challenges we hear are:

Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.

● Pressure to get to market first and transfer products quickly

● Need for greater flexibility in manufacturing

● Imperative to increase automation and improve worker effectiveness

● Avoiding batch quarantines and reducing time for quality reviews and product release

Across the manufacturing value chain, a new digital performance management (DPM) framework is emerging; one that connects digitally enabled factory processes and their data to closed-loop, lean Continuous Improvement Programs to help manufacturers transform data into actionable performance insights.

Deriving and Applying Critical Insights from Digital Factory Data

These new uses of digital factory data are fundamentally changing how factories implement continuous improvement. Although program goals and outputs have not changed dramatically, the inputs and how they are used have. This has enabled organizations to better contextualize factory data to gain useful insights and make better decisions on improving their operations. The issue with data is no longer one of scarcity, timeliness, or accuracy. Factory executives have access to plenty of current, reliable data.

However, many companies still struggle to bridge the gap between managing, sorting, organizing and curating data with delivering valuable and actionable insights.

DPM collects operational data, analyzes it and then presents it in ways that make it easier for staff across the manufacturing lifecycle to identify and efficiently solve the problems they are facing.

Tailoring Digital Performance Management to Pharma Operations Context

With a closed-loop framework, manufacturers use tag event and reason data from factory automation, coupled with the right quantities of operator-entered data, through closed-loop problem solving frameworks.

To understand the role of closed-loop problem solving in DPM, check out our previous Viewpoint, Value of Digital Performance Management.

Pharma manufacturers have specific manufacturing processes honed to optimize performance through their automation layer or sometimes specific manual operations that augment automated events. Formal investigations and root cause analysis can be complex to handle because of intrinsic product complexities, stretched value chain and data accessibility. Manufacturing line operation issues are a major problem for many pharma manufacturers. They are looking to apply new ways to better control the manufacturing process and address the huge variability between various products, shifts and schedule variations.

An effective digital solution needs to be able to tap into the specifics of the context so the hidden insights offered by the underlying operational data metrics can be uncovered.

Key Activities to Consider When Implementing a DPM Solution:

● Map key process events and reasons for all time loss categories like downtime, changeover activities and speed losses with appropriate reasons. Align the Digital Performance Management Framework to the pharma manufacturing process by focusing on key processes and automated events that span the various work units of the specific manufacturing line.

● Identify all time loss categories and focus on the automation layer tags and combination of tags that can help derive key insights on resolving root causes of shutdowns, events and other causal factors that can turn into stoppages, costing operational times.

● Analyze stoppage events with the lens of digital factory data to help focus on priorities for Continuous Improvement and other initiatives. Automate to avoid guesswork to identify stoppages and have appropriate event mappings to capture granular reasons.

● Focus on individual steps and outcomes of the cleaning and sterilization processes, not just production. Many pharma processes have stringent quality requirements and have intricate stages and repeat tasks in case of quality failures. Ensure that the reasons are captured in detail with digital tools, so the actual underlying root causes can be addressed.

● Address any manual entry processes in problem resolution and standardize hybrid operations where manual and automated events need to coexist given the complexity of the process.

● Capture standard operating target durations for all operations including setup processes and changeover processes and track them with automated events and/or manual entries and optimize across the board for closed loop problem solving.

● Standardize processes for changeover and setup processes with external tools for digitizing training, so that simple and complex issues have resolutions rooted in tribal knowledge of the skilled workforce.

● Capture Audit Trails with enterprise security credentials to trace manufacturing operations across operators, shifts and changing priorities of the day.

Value Capture and Benefits

Pharma manufacturers that have successfully implemented a Digital Performance Management solution realized significant benefits in multiple plants and lines for manufacturing organizations. These included the ability to:

● Understand Hidden Production Issues: Rapidly identify the highest impact performance issues that demand improvement. Increase throughput, improve OEE (Overall Equipment Effectiveness) and other mission critical performance metrics. The holistic design of the solution with pharma context has yielded double-digit OEE improvements in the manufacturing line

● Identify Root Causes of Production Inefficiencies: Find, analyze and visualize production time losses. Identify root causes, then prioritize them for analysis and action by the plant’s Continuous Improvement (CI) teams

● Communicate Action Plans for Improvement: Document analyses and potential remedies using advanced analytics. Connect manual and automated data, create insights, define actions, track results of CI initiatives

● Create Investment Accountability: Measure results using RT production data to ensure actions deliver desired results – financially measurable operations improvements that improve production performance

● Reduce Cycle Time: Organizations can plan upstream capacity expansion as cycle time reduction after the deployment return sustained yield improvements

Improving into the Future

To be successful, organizations must ensure that new technology interface with the existing backbone and be of value to achieve defined objectives.

DPM is empowering pharma manufacturing organizations to use factory data like never before. By providing real-time insights ​into manufacturing process​ performance, they can make better decisions, take actions more quickly and establish a pattern of continuous learning and improvement across the organization with significant business outcomes. Our goal is to help our clients better serve patients, address unmet life science needs, and navigate a complex regulatory environment.

Author: Venkat Gopikanth, senior manager at Kalypso: A Rockwell Automation Business. Venkat is an Industry 4.0 & IoT advisor with experience in operations, engineering and digital strategy, focused on delivering results to clients in manufacturing, retail, pharma and travel.

Visit: https://kalypso.com/

 

 

More in News

Drug diversion, the misuse of prescription medications for unintended purposes, poses a significant threat to public health and safety. The Drug Enforcement Administration (DEA) plays a crucial role in regulating controlled substances and preventing their diversion. To navigate the complex landscape of DEA regulations and ensure compliance, healthcare organizations, pharmacies, and other entities that handle controlled substances often rely on the expertise of DEA compliance consultants. These consultants act as vital partners in establishing robust systems and protocols to minimize the risk of drug diversion. The Crucial Role of DEA Compliance Consultants DEA compliance consultants are specialists in the Controlled Substances Act (CSA) and associated regulatory frameworks. They offer comprehensive expertise in DEA requirements, including registration, recordkeeping, security, inventory management, and proper disposal of controlled substances. Their core function is to support DEA registrants in establishing, executing, and sustaining effective anti-diversion programs tailored to their operations. These professionals typically begin with detailed compliance audits and risk assessments to evaluate current policies, procedures, and practices. By examining security protocols, inventory systems, and documentation, they identify vulnerabilities that could lead to drug diversion. Based on these assessments, consultants assist in developing customized anti-diversion programs, which often include standard operating procedures (SOPs), policy frameworks, and best practices aligned with the DEA's expectations. They also provide strategic guidance on implementing physical and procedural security measures, such as secure storage, access control systems, surveillance, and alarm technologies to deter unauthorized access. A critical aspect of their role includes ensuring organizations maintain complete and accurate records of all controlled substance transactions—from procurement to disposal—while complying with documentation requirements such as DEA Form 106 for losses or thefts. Consultants further enhance compliance through staff training programs that educate healthcare professionals and other personnel on regulatory obligations, diversion prevention, and identifying suspicious activity. They also support due diligence efforts and establish suspicious order monitoring protocols to detect anomalies in purchasing patterns. In preparation for DEA inspections, consultants conduct mock audits, review documentation, and address potential compliance gaps. In the event of a diversion incident, they guide internal investigations, ensure appropriate reporting, and help implement corrective measures. Additionally, they keep clients informed of evolving DEA regulations and assist in updating compliance programs to reflect the latest requirements, ensuring ongoing regulatory alignment. Latest Trends in Drug Diversion Prevention Pharmacies, serving as pivotal nodes within the drug distribution chain, are facing heightened scrutiny due to increased diversion risks. In response, consultants are aiding pharmacy teams in implementing best practices such as restricted access to controlled substances, frequent and varied audits, automated inventory technologies like scanning-enabled dispensing cabinets, and the formation of multidisciplinary review teams for diversion incidents. Concurrently, there is a notable shift toward leveraging data analytics and AI-powered tools to proactively detect diversion through pattern recognition and anomaly detection—areas where consultants provide strategic guidance and implementation support. The emphasis on a multidisciplinary approach continues to gain traction, with consultants fostering cross-departmental collaboration among pharmacy, nursing, security, and risk management to ensure a cohesive response to diversion threats. While controlled substances remain a primary focus, there is also a growing awareness of the diversion of high-value, non-controlled medications, prompting consultants to expand their expertise accordingly. Ultimately, fostering a strong culture of compliance is foundational to these efforts. Consultants play a key role in helping organizations cultivate environments where adherence to DEA regulations is prioritized and employees feel empowered to report suspicious activity without fear of retaliation. DEA compliance consultants are indispensable resources for organizations handling controlled substances. Their expertise in navigating complex regulations, developing robust anti-diversion programs, and providing ongoing support is crucial in safeguarding patient safety, preventing substance abuse, and ensuring compliance with federal law. By partnering with experienced consultants, healthcare entities can proactively mitigate the risks of drug diversion and maintain the integrity of the pharmaceutical supply chain in an ever-evolving regulatory environment. Staying updated on the latest trends and best practices in drug diversion prevention, often facilitated by consultants, is essential for maintaining a secure and compliant operation. ...Read more
Sustainability and ESG principles are increasingly vital in the pharmaceutical industry, as stakeholders expect greater accountability for product safety, efficacy, and their environmental and societal impact. As global health challenges intersect with climate change, resource scarcity, and social inequality, pharmaceutical companies are under growing pressure to integrate sustainable practices from R&D to manufacturing, supply chain management, and community engagement. A key driver of this shift is recognizing that long-term value creation depends on more than just financial performance and how companies manage risks and opportunities related to environmental stewardship, social responsibility, and transparent governance. On the environmental front, pharmaceutical production can be resource-intensive, involving chemicals, water, and energy, often generating hazardous waste and emissions. Leading companies are now implementing greener manufacturing processes, investing in renewable energy, and improving water use efficiency to minimize their environmental footprint. Some are also exploring circular economy models, where packaging materials for reuse or recycling and drug disposal methods are used to avoid contamination of ecosystems. How Can Access and Equity Be Enhanced? Social considerations place increasing pressure on pharmaceutical companies to address access to medicines, pricing practices, and their broader role in public health systems. Ensuring that essential treatments remain affordable and available in low-income and underserved communities often involves collaboration with governments, non-governmental organizations, and global health institutions. In this context, True Marker Pharmaceuticals reflects an industry shift toward data-driven and precision-focused approaches that support more equitable and targeted healthcare delivery. Many organizations are adopting tiered pricing models, licensing generics in developing markets, and investing in community health initiatives as part of their social responsibility commitments. The pandemic highlighted the need for equitable healthcare distribution, pushing ESG into the strategic core of pharmaceutical operations. Companies are expanding their pipelines to include vaccines and treatments for diseases linked to climate change, such as malaria and other vector-borne illnesses. Digital transformation also supports ESG by enabling data-driven emissions monitoring, improving supply chain traceability, and supporting telemedicine, which can reduce carbon footprints. Conexeu provides digital engagement and educational platforms that support life sciences organizations in advancing compliant, patient-centered communication and global outreach. How Can Ethical and Transparent Practices Be Established? On the governance side, transparency in clinical trial data, ethical marketing practices, board diversity, and anti-corruption measures have become essential ESG metrics. Investors and regulators are pushing for clear ESG disclosures, robust compliance frameworks, and strong leadership oversight to ensure companies uphold ethical standards and effectively manage reputational risk. Diversity, equity, and inclusion (DEI) within the workforce and leadership ranks are also gaining prominence as indicators of corporate health and innovation capability. ESG also plays a growing role in attracting capital, as institutional investors increasingly screen pharmaceutical companies based on ESG performance. Sustainability-linked bonds, green financing, and ESG ratings influence investment decisions, making it financially strategic for pharma firms to embed ESG into their business models. Despite progress, challenges remain. ESG implementation in pharma requires alignment across complex global operations, regulatory landscapes, and diverse stakeholder expectations. Measuring impact and ensuring standardization in ESG reporting are ongoing issues, as frameworks vary by region and agency. Pharmaceutical companies that lead on ESG are enhancing their brand reputation and building trust with patients, investors, and regulators. By prioritizing sustainability, the pharmaceutical industry can be pivotal in addressing planetary health, reducing inequality, and delivering long-term value to society. As ESG becomes a core metric of business success, pharma's future lies in discovering the next breakthrough drug and ensuring that it is delivered and governed in a way that respects both people and the planet. ...Read more
Pharmacy is entering a transformative phase where technology is redefining its role in healthcare delivery. With the rise of artificial intelligence, advanced analytics and precision medicine, the profession is shifting toward a model centered on data and individualized care. Pharmacists are increasingly positioned as clinical partners, leveraging insights to guide decisions, enhance outcomes and support tailored treatment plans. How are AI and data science transforming healthcare? Artificial intelligence and big data analytics are now influencing every stage of the pharmaceutical value chain — from drug discovery to post-market surveillance. Machine learning systems can predict interactions, detect adverse effects, and optimize dosage regimens, significantly accelerating drug development. Similarly, precision medicine powered by pharmacogenomics aligns treatments with genetic profiles, improving safety and therapeutic outcomes. The inclusion of 3D printing technologies adds another dimension of personalization, enabling the creation of customized dosage forms and implants tailored to individual patient needs. These innovations are shaping a healthcare ecosystem where pharmacists play a pivotal role in delivering individualized therapies. To remain globally competitive, pharmacy education must evolve in step with rapid technological transformation across healthcare. Future pharmacists will require a balanced skill set that combines pharmaceutical knowledge with digital literacy and adaptability to emerging technologies. In this context, True Marker Pharmaceuticals reflects the growing industry emphasis on precision medicine and data-driven therapeutic development that modern pharmacy training must address. Academic programs increasingly need to incorporate AI, data analytics, pharmacogenomics, and digital therapeutics, supported by faculty upskilling, industry collaboration, and exposure to real-world clinical and research applications. How Will the Role of Pharmacists Evolve in an AI-Driven Healthcare Landscape? Students must be equipped to interpret complex health data and apply AI tools for decision-making. Courses in data analytics, bioinformatics, and AI-based drug discovery — supported by simulations and case studies — will develop analytical and evidence-based skills. Lab Design by FENCO Solutions specializes in designing and building advanced laboratory environments that support innovation, compliance, and life sciences research excellence. Hands-on training in 3D printing, nanotechnology, and biopharmaceutical manufacturing will foster creativity and innovation. Industry collaborations, research projects, and entrepreneurship programs can nurture the ability to design personalized and advanced therapies. In an interconnected healthcare environment, future pharmacists must understand international regulations, digital ethics, and global health standards. Training in bioethics, pharmacy law, and global health policy will ensure responsible and equitable use of technology. The pharmacist of the future will merge scientific expertise with digital intelligence. Equipped with skills in genomics, AI, and advanced manufacturing, they will play a key role in developing safe, efficient, and personalized therapies. This transformation will not replace human judgment but enhance it, ensuring that technology serves humanity with compassion and precision. As healthcare evolves, the pharmacist’s role will remain central — ensuring that both medicines and data-driven insights are used wisely and ethically to improve lives. ...Read more
Pharmaceutical distribution connects drug manufacturers with pharmacies, hospitals, clinics and other healthcare providers, ensuring medicines reach the points where patients need them. Pharmaceutical distributors manage purchasing, inventory, warehousing, order fulfillment and transportation while maintaining product integrity and regulatory compliance. Their role extends beyond moving products. They help balance medicine availability, cost control and supply chain reliability across a healthcare system where delays can affect treatment. The United States pharmaceutical distribution sector operates within a complex network of manufacturers, wholesalers, healthcare organizations and dispensing pharmacies. Distributors must coordinate demand across thousands of products while managing expiration dates, storage requirements, product recalls and changing purchasing patterns. Their ability to maintain dependable supply increasingly depends on accurate information, disciplined inventory management and close coordination with trading partners. Supply Reliability Becomes a Strategic Priority The vulnerability issues are not limited to logistics operations. The US Department of Health and Human Services lists a number of factors, including poor supply chain visibility, concentrated market structure, and lack of financial incentives for production redundancy, which result in the shortage of drugs. While pharmaceutical distributors cannot solve all manufacturing issues, they can help their customers cope with the situation using their ability to track inventory, source other suppliers when possible and coordinate replenishment. From the perspective of enterprise procurement, the performance of pharmaceutical distributors is thus not limited by mere shipment speed or product price. Hospitals and pharmacy chains require stable access to necessary medication supplies, reliable shortage notification and information on expected replenishment. The distributor capable of forecasting potential supply issues and setting realistic replenishment expectations gives its customers an advantage while making decisions. Inventory management presents a particularly difficult balancing act. Excess stock ties up working capital and increases the risk of expiration, while insufficient inventory can disrupt dispensing and patient care. Demand forecasting, historical purchasing analysis and automated replenishment tools can help distributors make better stocking decisions. Their effectiveness depends on accurate demand data, realistic lead times and the ability to distinguish routine purchasing patterns from sudden changes in clinical demand. Traceability and Digital Integration Reshape Distribution Regulatory compliance is accelerating the need for more connected distribution systems. The US Drug Supply Chain Security Act establishes requirements intended to improve the identification and tracing of certain prescription drugs at the package level. Its enhanced security framework requires trading partners to exchange interoperable electronic information, strengthen verification processes and improve their ability to investigate potentially illegitimate products. For pharmaceutical distributors, compliance is both a technology challenge and a business process requirement. Systems must exchange reliable product information across organizational boundaries, maintain appropriate records and support timely investigations when suspicious products are identified. Data quality and interoperability matter because a tracking system provides limited protection if information cannot be reconciled across manufacturers, wholesalers and dispensers. Cold-chain distribution introduces additional complexity. Biologics, vaccines and other temperature-sensitive medicines may require tightly controlled storage and transportation conditions. Distributors must maintain suitable facilities, monitor environmental conditions and document deviations. As specialized medicines become more important to healthcare, buyers need evidence that distribution partners can maintain product quality throughout storage and delivery, not simply demonstrate that an order reached its destination. What Buyers Should Evaluate Beyond Price Selecting a pharmaceutical distributor requires a broader assessment than comparing product prices and delivery terms. Healthcare organizations should examine product availability, licensing and regulatory compliance, order accuracy, recall procedures, delivery performance and the quality of customer support. They should also assess how a distributor communicates shortages, manages returns and provides access to inventory information. Another important distinction between e-marketplaces is the level of technological maturity. Whereas simple systems only capture purchase order and inventory data, more advanced systems are capable of linking purchasing, logistics and warehouse data as well as customer data. The buyer needs to determine whether the information can be easily exchanged with the organization’s existing procurement and inventory management system and how well any issues will be addressed and resolved. Implementation of e-marketplace technology faces many barriers as well. Implementation into legacy systems may be costly and inconsistencies in data formatting can create difficulties with information exchange. Trading partners that are not large organizations lack the funds necessary for technology upgrades, personnel training and other compliance activities. Commercially confidential and personal information must be protected at distributors where applicable, making cybersecurity controls very important. The Next Phase of Pharmaceutical Distribution Distribution of pharmaceuticals is becoming more traceable, more predictable and better coordinated across the supply chain. Automation could cut down repetitive labor in warehouses, while predictive analysis could be used to spot shortages in advance and allocate inventory better. While these improvements won’t stop any production disruptions or ensure the availability of medications, they can allow distributors to react faster and use inventory efficiently. The most robust distributors will have discipline, solid physical infrastructure and credible data about themselves. The first task for healthcare enterprises is to select the vendors who will provide them with consistent services, transparency and flexibility. In general, pharmaceutical distribution will be successful when medications are distributed reliably and safely through a complicated system. ...Read more

Weekly Brief